NAV

Rexin G

Identification

Generic Name
Rexin G
DrugBank Accession Number
DB16450
Background

Rexin-G is a tumor-targeted, injectable retroviral vector carrying a mutant form of the cyclin G1 gene. It is under development by Epeius Biotechnologies for the potential treatment of metastatic cancer. It is also being investigated for preventing SARSCOV-2 viral entry.

Type
Biotech
Groups
Investigational
Biologic Classification
Gene Therapies
Other gene therapies
Synonyms
  • DeltaRex-G
  • DeltaRex-G Retroviral Vector Encoding a Cyclin G1 Inhibitor
  • Mx-dnG1 retroviral vector
  • retroviral expression vector bearing anti-cyclin G1 gene construct
  • Rexin-G
External IDs
  • Mx-dnG1

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Avoid life-threatening adverse drug events
Improve clinical decision support with information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events & improve clinical decision support.
Learn more
Pharmacodynamics

Not Available

Mechanism of action

Rexin G is a non-pathogenic entity that mimics SARS-COV2 by binding to receptors to gain entry into human cells. It is being investigated for preventing SARSCOV-2 viral entry, and also acts as an inhibitor of the cyclin G1 pathway.

Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates.
Learn more
Improve decision support & research outcomes with our structured adverse effects data.
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Classification
Not classified
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
1023923-93-4

References

General References
  1. Al-Shihabi A, Chawla SP, Hall FL, Gordon EM: Exploiting Oncogenic Drivers along the CCNG1 Pathway for Cancer Therapy and Gene Therapy. Mol Ther Oncolytics. 2018 Dec 12;11:122-126. doi: 10.1016/j.omto.2018.11.002. eCollection 2018 Dec 21. [Article]
  2. External Link [Link]
  3. External Link [Link]
Wikipedia
Rexin_G

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1, 2Not Yet RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Cytokine Storm / Respiratory Distress Syndrome, Acute (ARDS)1
Not AvailableAvailableNot AvailableChondrosarcomas / Chordomas / Malignant Neoplasm of Pancreas / Malignant Peripheral Nerve Sheath Tumour (MPNST) / Sarcoma, Osteogenic / Sarcomas / Soft Tissue Sarcoma (STS)1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available

Drug created at January 21, 2021 01:43 / Updated at February 13, 2021 10:53